Former Allergan exec heads to Revance as it challenges Botox; Mark Pruzanski surrounds himself with more teammates
→ Revance feels like it has a competitive advantage over AbbVie’s blockbuster Botox with only biannual injections of its freshly approved Daxxify, as opposed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
